EP
ORIC icon

Essential Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Essential Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.57K Sell
514
-39
-7% -$354 ﹤0.01% 1496
2026
Q1 		$7.01K Buy
553
+1
+0.2% +$11 ﹤0.01% 1412
2025
Q4 		$4.51K Hold
552
– – ﹤0.01% 1473
2025
Q3 		$6.62K Hold
552
– – ﹤0.01% 1314
2025
Q2 		$5.6K Buy
+552
New +$3.71K ﹤0.01% 1018

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's ORIC Position: Q2 2026 in Review

Essential Partners reduced its Oric Pharmaceuticals (ORIC) stake by 7.1% in Q2 2026, selling an estimated $354 and leaving 514 shares worth $5.57K. The position accounts for ﹤0.01% of the portfolio, ranked #1496.

Essential Partners first reported a position in ORIC in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.01K in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Essential Partners held 514 shares of Oric Pharmaceuticals worth $5.57K as of Q2 2026.
  • Essential Partners sold 39 Oric Pharmaceuticals shares in Q2 2026, an estimated $354.
  • Oric Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1496 holding.
  • Essential Partners first reported a position in Oric Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Oric Pharmaceuticals position peaked at $7.01K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.